Table 4 Association of biomarkers with odds of having an on or post-study SRE
| Â | Baseline | Change from Baseline to 12 Weeks | |||
|---|---|---|---|---|---|
Odds ratio (95% CI) | p-value | Odds ratio (95% CI) | p-value | ||
CTx | /10 unit change | 1.00 (0.94, 1.07) | 0.99 | 1.04 (0.95, 1.14) | 0.39 |
BSAP | /unit change | 1.03 (0.97, 1.09) | 0.36 | 0.90 (0.73, 1.11) | 0.32 |
TGF-β | /unit change | 1.05 (0.90, 1.23) | 0.54 | 0.98 (0.83, 1.16) | 0.83 |
Activin-A | /100 unit change | 0.98 (0.89, 1.07) | 0.60 | 0.99 (0.93, 1.04) | 0.64 |
NTx | /10 unit change | 1.00 (0.97, 1.02) | 0.69 | 1.01 (0.97, 1.06) | 0.56 |
P1NP | /10000 unit change | 0.97 (0.79, 1.18) | 0.75 | 0.98 (0.80, 1.20) | 0.84 |
BSP | /10 unit change | 1.00 (0.63, 1.60) | 0.99 | 0.94 (0.60, 1.47) | 0.79 |
FACT-BP | /unit change | 1.13 (1.01, 1.28) | 0.041 | 0.99 (0.87, 1.14) | 0.93 |
BPI | /unit change | 1.03 (0.99, 1.08) | 0.16 | 1.00 (0.94, 1.06) | 0.93 |
Duration of bone metastases | /month | 1.03 (0.99, 1.08) | 0.14 | Â | Â |
Pre-Study SRE | Yes versus no | 7.50 (0.74, 75.72) | 0.088 | Â | Â |
Treatment Group | 2 versus 1 | 1.07 (0.18, 6.21) | 0.94 | Â | Â |